乙肝疫苗市場規模（按類型、患者類型、分銷管道、地區、範圍和預測）

乙肝疫苗市場規模及預測

預計 2024 年乙肝疫苗市場規模將達到 82.6 億美元，到 2032 年將達到 133.1 億美元，2026 年至 2032 年的複合年成長率為 4.6%。

乙肝疫苗用於預防感染B肝病毒，B肝病毒可導致肝硬化和肝細胞癌等嚴重的肝病。

這些疫苗透過刺激人體免疫系統產生針對B肝病毒的抗體來發揮作用。

此外，乙肝疫苗廣泛應用於新生兒和高風險成人族群的國家免疫計劃，被認為是預防B型肝炎感染及其併發症最有效的方法之一。

乙肝疫苗市場動態

關鍵市場促進因素

全球乙肝感染率上升：全球乙肝感染率上升是疫苗接種需求成長的主要促進因素。根據世界衛生組織 (WHO) 的數據，2019 年全球約有 2.96 億人患有慢性B肝，每年新增感染人數達 150 萬人。感染人數的上升凸顯了接種疫苗以防止疾病進一步傳播的必要性。

政府免疫接種計劃：許多國家已擴大其疫苗接種計劃，以對抗B型肝炎感染，市場規模也大幅擴張。例如，在美國，疾病預防控制中心 (CDC)建議所有嬰兒、19 歲以下未接種疫苗的兒童以及高風險成年人接種B型肝炎疫苗。到 2020 年，全球嬰兒疫苗接種覆蓋率將達到 85%，而 2000 年僅為 30%。

醫療保健意識提升和舉措：在新興國家，人們對B型肝炎的認知正在不斷提高，政府主導的衛生計畫正在推廣疫苗接種。例如，中國國家衛生健康委員會已啟動一項計劃，旨在透過加強疫苗接種來降低慢性B型肝炎的盛行率。根據2020年的一項研究，中國超過90%的兒童在一歲前接種了B型肝炎疫苗，這對市場成長至關重要。

主要挑戰

疫苗猶豫：儘管乙肝疫苗的有效性已被證實，但疫苗猶豫在某些地區仍然是一個重大挑戰。對疫苗安全性和有效性的誤解可能會阻礙疫苗接種率，並影響市場成長。

低溫運輸管理：B型肝炎疫苗在儲存和運輸過程中需要嚴格的溫度控制。維護低溫運輸帶來物流挑戰，尤其是在資源匱乏的地區，這會影響疫苗的分發和取得。

研發新疫苗高成本：開發新型改良B肝疫苗需要大量的研發成本。高成本阻礙了新進入者進入市場，並限制了該領域的創新。

主要趨勢：

更重視成人疫苗接種：儘管兒童疫苗接種計畫已經很完善，但人們越來越重視成人B型肝炎疫苗接種。這種趨勢源自於人們認知到許多成年人，特別是高風險族群，仍然沒有受到B型肝炎疫苗的保護。

治療性疫苗的研發：治療性B型肝炎疫苗的研究正在進行中，該疫苗可望治療慢性B型肝炎感染。如果成功，這些疫苗將顯著擴大市場規模，並徹底改變B型肝炎治療的格局。

擴大新興市場的疫苗生產：新興市場，尤其是亞洲市場，正朝著提高疫苗生產能力的方向發展。這有助於降低疫苗成本，並提高這些地區的疫苗供應。

乙肝疫苗市場區域分析

乙肝疫苗市場區域分析

北美：

根據Verified Market Research的數據，預計北美將在預測期內主導乙肝疫苗市場。北美市場受益於各國政府透過全面的疫苗接種計畫大力消除B型肝炎。例如，美國衛生與公眾服務部實施了“病毒性肝炎國家戰略計劃（2021-2025）”，旨在降低肝炎感染對公共衛生的威脅。該計劃提高了疫苗的可及性和覆蓋率，顯著促進了市場成長。美國疾病管制與預防中心（CDC）的數據顯示，2021年，美國超過90%的嬰兒在24個月大前接種了B型肝炎疫苗。

北美是乙肝流行率較高的地區，推動了疫苗接種的需求：光是在美國就有約120萬人患有慢性B肝，美國疾病管制與預防中心估計，2019年將有22,000例急性B肝新發病例。這種高疾病負擔正在推動疫苗和預防策略的採用率提高。

此外，預防多種疾病（包括B型肝炎）的聯合疫苗的使用是北美的主要驅動力。像Pediarix（一種包含乙肝疫苗的五價疫苗）這樣的疫苗的推出增加了市場佔有率，尤其是在兒童疫苗領域。政府強調聯合疫苗的免疫接種計劃進一步支持了這一趨勢。美國疾病管制與預防中心指出，為了提高免疫接種計畫的依從性，聯合疫苗的使用正在增加。

亞太地區：

預計亞太地區將在預測期內呈現最高成長。亞太地區是全球乙肝感染負擔最重的地區之一，推動了對疫苗的需求。根據世界衛生組織 (WHO) 的數據，全球超過 60% 的乙肝病毒攜帶者居住在亞洲，其中中國佔大多數。光是在中國，就有 7,000 萬人患有慢性B肝，每年約有 100 萬人死於B型肝炎相關併發症。如此高的病例數正推動該地區對疫苗的接受度。

亞太地區的國家免疫規劃為B肝疫苗市場提供了強而有力的支持。例如，中國政府的免疫規劃在出生後24小時內接種疫苗，兒童B肝疫苗接種率已超過90%。世界衛生組織2017年報告稱，西太平洋地區約85%的國家已實施全民乙肝疫苗接種，感染率顯著下降。

此外，製藥公司與研究機構之間的持續合作也推動了亞太地區市場的成長。 2022年4月，日本製藥公司鹽野義製藥株式會社與NEC株式會社合作，開發了一種針對B肝的新型疫苗，以治癒這種慢性感染疾病。在不斷成長的研發投入的支持下，此類合作正在推動先進疫苗的開發，促進該地區市場的快速擴張。

目錄

第1章 引言

• 市場定義
• 市場區隔
• 調查方法

第2章執行摘要

• 主要發現
• 市場概覽
• 市場亮點

第3章市場概述

• 市場規模和成長潛力
• 市場趨勢
• 市場促進因素
• 市場限制
• 市場機會
• 波特五力分析

4. 乙肝疫苗市場（依類型）

• 單一疫苗
• 聯合疫苗

5. 乙肝疫苗市場（依患者類型）

• 成人
• 孩子們

6. 乙肝疫苗市場（依分銷管道）

• 醫院藥房
• 零售藥局
• 網路藥局

第7章區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第8章市場動態

• 市場促進因素
• 市場限制
• 市場機會
• COVID-19 市場影響

第9章 競爭態勢

• 主要企業
• 市場佔有率分析

第10章 公司簡介

• Merck & Co., Inc.
• GlaxoSmithKline plc.
• Sanofi Pasteur
• Walgreens Boots Alliance, Inc.
• Serum Institute of India Pvt. Ltd.
• China National Biotec Group Co., Ltd.
• F. Hoffmann-La Roche Ltd.
• Mylan NV
• Shionogi & Co., Ltd.
• Abbott Laboratories

第11章 市場展望與機會

• 新興技術
• 未來市場趨勢
• 投資機會

第12章 附錄

• 簡稱列表
• 來源和參考文獻

Hepatitis B Vaccines Market Size and Forecast

Hepatitis B Vaccines Market size was valued at USD 8.26 Billion in 2024 and is projected to reach USD 13.31 Billion by 2032, growing at a CAGR of 4.6 % from 2026 to 2032.

Hepatitis B vaccines are used to prevent infection caused by the hepatitis B virus, which leads to serious liver diseases including cirrhosis and hepatocellular carcinoma.

These vaccines work by stimulating the body's immune system to produce antibodies against the hepatitis B virus.

Furthermore, hepatitis B vaccines are widely used in national immunization programs for newborns and high-risk adult populations and are considered one of the most effective ways to prevent hepatitis B infection and its complications.

Hepatitis B Vaccines Market Dynamics

The key market dynamics that are shaping the hepatitis B vaccines market include:

Key Market Drivers

Rising Global Prevalence of Hepatitis B: The rising prevalence of Hepatitis B infections worldwide is a major driver of vaccination demand. According to the World Health Organization (WHO), around 296 million individuals were living with chronic Hepatitis B infection in 2019, with 1.5 million new infections happening annually. The increasing number of cases highlights the need for immunizations to prevent the disease from spreading further.

Government Immunization Programs: Many nations are extending their immunization programs to combat Hepatitis B infections, considerably increasing the market. For example, the CDC advises that in the United States, Hepatitis B immunization is recommended for all infants, unvaccinated children under the age of 19, and at-risk adults. In 2020, global baby vaccination coverage reached 85%, up from 30% in 2000.

Increasing Healthcare Awareness and Initiatives: Increased awareness of Hepatitis B and government-led health programs in emerging nations are promoting vaccination adoption. For example, China's National Health Commission started an attempt to lower the prevalence of chronic Hepatitis B by boosting immunization. According to 2020 research, more than 90% of children in China have had Hepatitis B vaccinations by the age of one, which is essential for market growth.

Key Challenges:

Vaccine Hesitancy: Despite the proven efficacy of hepatitis B vaccines, vaccine hesitancy remains a significant challenge in some regions. Misconceptions about vaccine safety and efficacy hinder uptake rates, potentially impacting market growth.

Cold Chain Management: Hepatitis B vaccines require strict temperature control during storage and transportation. Maintaining the cold chain, especially in resource-limited settings, poses logistical challenges that affect vaccine distribution and availability.

High Cost of New Vaccine Development: The development of new and improved hepatitis B vaccines involves substantial research and development costs. These high costs are a barrier to market entry for new players and limit innovation in the field.

Key Trends:

Increasing Focus on Adult Vaccination: While childhood vaccination programs are well-established, there is a growing emphasis on adult hepatitis B vaccination. This trend is driven by the recognition that many adults remain unprotected against hepatitis B, particularly in high-risk groups.

Development of Therapeutic Vaccines: Research is ongoing into therapeutic hepatitis B vaccines that could potentially treat chronic hepatitis B infections. If successful, these vaccines could significantly expand the market and change the landscape of hepatitis B treatment.

Expansion of Vaccine Production in Emerging Markets: There is a trend towards increasing vaccine production capabilities in emerging markets, particularly in Asia. This is helping to reduce vaccine costs and improve availability in these regions.

Hepatitis B Vaccines Market Regional Analysis

The regional analysis of the hepatitis B vaccines market:

North America:

According to Verified Market Research, North America is estimated to dominate the hepatitis B vaccines market over the forecast period. The North American market benefits from strong governmental efforts to eliminate hepatitis B through comprehensive vaccination programs. For instance, the U.S. Department of Health & Human Services implemented the "Viral Hepatitis National Strategic Plan (2021-2025)" aimed at reducing hepatitis infections as a public health threat. This plan enhances vaccine accessibility and coverage, contributing significantly to the market's growth. According to the CDC, in 2021, over 90% of U.S. infants received the hepatitis B vaccine by 24 months of age.

North America has a notable prevalence of hepatitis B, which drives the demand for vaccination. In the United States alone, approximately 1.2 million people are chronically infected with hepatitis B. The CDC highlights that 22,000 new acute hepatitis B cases were estimated in 2019. This high disease burden prompts increased adoption of vaccines and preventive strategies.

Furthermore, the use of combination vaccines that protect against multiple diseases, including hepatitis B, is a key driver in North America. The introduction of vaccines like Pediarix (a 5-in-1 vaccine that includes hepatitis B) has expanded the market share, particularly in pediatric vaccinations. This trend is further supported by government-backed vaccination schedules that emphasize combination vaccines. The CDC notes that combination vaccines are increasingly used to improve adherence to immunization programs.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. The Asia-Pacific region has one of the highest burdens of Hepatitis B infections globally, driving the demand for vaccines. According to the World Health Organization (WHO), more than 60% of the world's Hepatitis B carriers live in Asia, with China accounting for a large portion. In China alone, 70 million people are chronically infected, and around 1 million people die each year due to Hepatitis B-related complications. This significant patient population fuels vaccine adoption across the region.

National immunization programs in Asia-Pacific are strongly supporting the hepatitis B vaccine market. For example, the Chinese government's immunization program has achieved over 90% Hepatitis B vaccine coverage among children, with a birth dose administered within 24 hours of birth. In 2017, WHO reported that around 85% of countries in the Western Pacific Region implemented universal Hepatitis B immunization, leading to a significant reduction in infection rates.

Furthermore, ongoing collaborations between pharmaceutical companies and research institutions are driving market growth in Asia-Pacific. In April 2022, Japanese pharmaceutical company Shionogi & Co., Ltd. partnered with NEC Corporation to develop a novel vaccine targeting Hepatitis B, aimed at curing chronic infections. These collaborations, supported by growing R&D investments, are boosting the development of advanced vaccines, contributing to the rapid market expansion in the region.

Hepatitis B Vaccines Market: Segmentation Analysis

The Hepatitis B Vaccines Market is segmented based on Type, Patient Type, Distribution Channel, and Geography.

Hepatitis B Vaccines Market, By Type

• Mono Vaccines
• Combination Vaccines

Based on Type, the market is segmented into Mono Vaccines and Combination Vaccines. The combination vaccines segment is estimated to dominate the hepatitis B vaccines market due to its ability to protect against multiple diseases in a single shot. These vaccines, which typically combine hepatitis B protection with other antigens such as those for diphtheria, tetanus, and pertussis, are increasingly preferred in national immunization programs. The convenience of fewer injections for patients and healthcare providers, along with reduced administration costs, are key factors driving the popularity of combination vaccines. While mono vaccines remain important, particularly for adult vaccination, the efficiency and cost-effectiveness of combination vaccines are cementing their dominant position in the market.

Hepatitis B Vaccines Market, By Patient Type

• Adult
• Pediatric

Based on Patient Type, the market is segmented into Adult and Pediatric. The pediatric segment is estimated to grow at the highest CAGR in the hepatitis B vaccines market. This growth is primarily driven by the widespread implementation of universal hepatitis B vaccination programs for newborns and infants in many countries. These programs, recommended by the World Health Organization, aim to prevent mother-to-child transmission and early childhood infections. The high birth rates in developing countries, coupled with increasing awareness about the importance of early vaccination, are fueling the growth of the pediatric segment. While adult vaccination remains crucial, especially for high-risk groups, the focus on preventing hepatitis B infection from the earliest stages of life is expected to maintain the pediatric segment's dominant position in the market.

Hepatitis B Vaccines Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on the Distribution Channel, the market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment is estimated to dominate the market over the forecast period. This dominance is attributed to the fact that a significant portion of hepatitis B vaccinations are administered in hospital settings, particularly for newborns and high-risk patients. Hospitals are often the primary sites for implementing national immunization programs, especially for infant vaccinations. Additionally, hospital pharmacies are well-equipped to handle the storage and distribution requirements of vaccines, including maintaining the cold chain. The trend towards combination vaccines, which are often administered as part of comprehensive immunization schedules in hospital settings, further reinforces the dominance of the hospital pharmacies segment.

Hepatitis B Vaccines Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on Geography, the hepatitis B vaccines market is classified into North America, Based on geography, the Hepatitis B Vaccines Market is classified into North America, Europe, Asia-Pacific, and the Rest of the World. The North American region is expected to dominate the market during the forecast period due to several key factors. A high prevalence of hepatitis B in the United States, with approximately 1.2 million people chronically infected, drives a strong demand for vaccines. Additionally, comprehensive immunization programs such as the U.S. Department of Health & Human Services' "Viral Hepatitis National Strategic Plan (2021-2025)" aim to increase vaccine coverage across all population groups. The region's strong healthcare infrastructure and significant investments in vaccine development also contribute to this market leadership.

Key Players

• The "Hepatitis B Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are GlaxoSmithKline plc, Merck & Co., Inc., Sanofi Pasteur, Dynavax Technologies Corporation, LG Chem, Serum Institute of India, Bharat Biotech, Biological E Limited, Crucell (Johnson & Johnson), and VBI Vaccines Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Hepatitis B Vaccines Market Recent Developments
• In September 2023, Dynavax Technologies Corporation announced that positive Phase 1 clinical trial results had been obtained for its next-generation hepatitis B vaccine candidate. The vaccine demonstrated a favorable safety profile and robust immune responses, potentially offering improved protection against hepatitis B.
• In March 2023, Sanofi Pasteur launched a new hexavalent vaccine in Europe that protects against six diseases, including hepatitis B. This combination vaccine is designed to simplify childhood immunization schedules and improve vaccination coverage.
• In December 2022, the World Health Organization prequalified a new pediatric hepatitis B vaccine developed by LG Chem. This prequalification allows the vaccine to be procured by UN agencies and Gavi, the Vaccine Alliance, for use in global immunization programs.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Hepatitis B Vaccines Market, By Type

• Mono Vaccines
• Combination Vaccines

5. Hepatitis B Vaccines Market, By Patient Type

• Adult
• Pediatric

6. Hepatitis B Vaccines Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Merck & Co., Inc.
• GlaxoSmithKline plc.
• Sanofi Pasteur
• Walgreens Boots Alliance, Inc.
• Serum Institute of India Pvt. Ltd.
• China National Biotec Group Co., Ltd.
• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Shionogi & Co., Ltd.
• Abbott Laboratories

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References